➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
AstraZeneca
Express Scripts
Baxter

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

faslodex Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Faslodex, and what generic alternatives are available?

Faslodex is a drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-one patent family members in forty countries.

The generic ingredient in FASLODEX is fulvestrant. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the fulvestrant profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Faslodex

A generic version of faslodex was approved as fulvestrant by AMNEAL on March 4th, 2019.

  Try it Free

Drug patent expirations by year for faslodex
Drug Prices for faslodex

See drug prices for faslodex

Recent Clinical Trials for faslodex

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CelcuityPhase 2
Seattle Genetics, Inc.Phase 2
Criterium, Inc.Phase 2

See all faslodex clinical trials

Paragraph IV (Patent) Challenges for FASLODEX
Tradename Dosage Ingredient NDA Submissiondate
FASLODEX INJECTABLE;INTRAMUSCULAR fulvestrant 021344 2009-10-01

US Patents and Regulatory Information for faslodex

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 AO RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 AO RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 AO RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 AO RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for faslodex

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Try it Free ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Try it Free ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Try it Free ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Try it Free ⤷  Try it Free
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for faslodex

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138504 2004C/004 Belgium ⤷  Try it Free PRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311
0138504 91068 Luxembourg ⤷  Try it Free 91068, EXPIRES: 20091002
0138504 SPC/GB04/009 United Kingdom ⤷  Try it Free PRODUCT NAME: FULVESTRANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/03/269/001 20040310
0138504 300158 Netherlands ⤷  Try it Free 300158, 20041002, EXPIRES: 20091001
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
AstraZeneca
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.